4 Small-Cap Biotech Stars Real Money Pro($)

I'm still enthusiastic about the sector, but it is critical to also be prudent.
The 50-day moving average is crossing the 200-day for a bullish golden cross; go long here.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
The story of Workday, Valeant and Salesforce illustrates a common investing mistake.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Check out GSK's well developed base pattern.
Novartis has seen some very aggressive buying the past five months -- time to join in.
SNY has become much stronger since late October; buy here and above $44.
If you play strong defense, be prepared to change course very quickly.
Readers want to know what to do with the two biotech names, which are headed in opposite directions.

Columnist Conversations

SPX weekly View Chart »  View in New Window » $SPX Daily


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.